常规对比常规联合氟昔洛韦(18F)正电子发射断层扫描/计算机断层扫描引导的前列腺切除术后放疗治疗前列腺癌的随机试验:体积与患者报告毒性分析
这项随机试验纳入165例前列腺切除术后可检测到前列腺特异性抗原的患者,比较常规计划(无PET)与联合氟昔洛韦(18F)PET/CT计划对临床靶体积和患者报告毒性的影响。结果显示PET组临床靶体积适度增大,但患者报告毒性无显著差异。
要点
- 氟昔洛韦(18F)PET/CT引导计划使临床靶体积适度增大。
- 患者报告毒性在两组间无显著差异。
- 中位随访3.52年,长期患者报告毒性无显著差异。
核心结论
- 尽管纳入氟昔洛韦(18F)PET后临床靶体积增大,长期随访未发现患者报告毒性效应显著差异。
研究设计与样本
- 2012年至2019年随机对照试验,纳入165例前列腺切除术后可检测到前列腺特异性抗原的患者,随机分为无PET组(82例)和PET组(83例)。
主要发现
- PET纳入前,组1与组2的平均CTV1为427.6 vs 452.2 mL(P=0.462),CTV2/CTV为137.18 vs 134.2 mL(P=0.669)。
- PET纳入后,CTV1为454.57 vs 461.33 mL(P=0.003),CTV2/CTV为134.14 vs 135.61 mL(P<0.001),均适度增大。
- PET前后直肠和膀胱的V40 Gy(P=0.402和P=0.522)及V65 Gy(P=0.157和P=0.182)无显著差异,但阴茎球剂量在PET后显著增加(V40 Gy和V65 Gy的P均<0.001)。
- 单变量和多变量分析中,治疗组对任何EPIC-CP子域均不显著;国际前列腺症状评分和EPIC-CP线性混合模型在组间无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Postprostatectomy radiation therapy planning with fluciclovine (18F) positron emission tomography (PET)/computed tomography has demonstrated improved disease-free survival over conventional only (computed tomography- or magnetic resonance imaging-based) treatment planning. We hypothesized that incorporating PET would result in larger clinical target volumes (CTVs) without increasing patient-reported toxic effects. METHODS AND MATERIALS: From 2012 to 2019, 165 postprostatectomy patients with detectable prostate-specific antigen were randomized (arm 1 [no PET]: 82; arm 2 [PET]: 83). Prostate bed target volumes with (CTV1: 45.0-50.4 Gy/1.8 Gy) or without (CTV2/CTV: 64.8-70.2 Gy/1.8 Gy) pelvic nodes, as well as organ-at-risk doses, were compared pre- versus post-PET (arm 2) using the paired t test and between arms using the t test. Patient-reported outcomes used International Prostate Symptom Score and Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP). Univariate and multivariable analyses were performed and linear mixed models were fitted. RESULTS: Median follow-up of the whole cohort was 3.52 years. All patients had baseline patient-reported outcomes, 1 patient in arm 1 and 3 patients in arm 2 withdrew, and 4 arm 2 patients had extrapelvic uptake on PET with radiotherapy aborted, leaving 81 (arm 1) and 76 patients (arm 2) for analysis of toxic effects. Mean CTV1 (427.6 vs 452.2 mL; P = .462, arm 1 vs arm 2) and CTV2/CTV (137.18 vs 134.2 mL; P = .669) were similar before PET incorporation. CTV1 (454.57 vs 461.33 mL; P = .003) and CTV2/CTV (134.14 vs 135.61 mL; P < .001) were modestly larger after PET incorporation. Although V40 Gy (P = .402 and P = .522 for rectum and bladder, respectively) and V65 Gy (P = .157 and P = .182 for rectum and bladder, respectively) were not significantly different pre- versus post-PET, penile bulb dose significantly increased post-PET (P < .001 for both V40 Gy and V65 Gy). On univariate and multivariable analyses, arm was not significant for any EPIC-CP subdomain. International Prostate Symptom Score and EPIC-CP linear mixed models were not significantly different between arms. CONCLUSIONS: Despite larger CTVs after incorporation of fluciclovine (18F) PET, we found no significant difference in patient-reported toxic effects with long-term follow-up.
引用
- Dhere VR, Schuster DM, Goyal S, et al. Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomography-Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic Effects. Int J Radiat Oncol Biol Phys. 2022. PMID: 35417762. doi:10.1016/j.ijrobp.2022.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。